ABOUT

Freeline is a clinical-stage biotechnology company focused on developing transformative gene therapies for people with inherited systemic debilitating diseases. Headquartered in the UK, NASDAQ quoted and operating in both Germany and the US, Freeline has strong ambitions for continued growth within both established and new territories.

With a vision to build and advance a pipeline of curative treatments to make a life-changing impact, Freeline’s purpose-led strategy is focused on transforming the lives of patients with haemophilia B, Fabry disease and other inherited, chronic diseases.